دورية أكاديمية
SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021
| العنوان: | SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021 |
|---|---|
| المؤلفون: | Lewis, Hc, Ware, H, Whelan, M, Subissi, L, Li, Z, Ma, X, Nardone, A, Valenciano, M, Cheng, B, Noel, K, Cao, C, Yanes-Lane, M, Herring, B, Talisuna, A, Nsenga, N, Balde, T, Clifton, Da, van Kerkhove, M, Buckeridge, Dl, Bobrovitz, N, Okeibunor, J, Arora, Rk, Bergeri, I, Collaborator Group, Unity Studies |
| المساهمون: | WHO, Regional Office for Africa Brazzaville, Republic of the Congo, World Health Organisation (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), University of Calgary, University of Waterloo Waterloo, University of Toronto, EpiConcept Paris, McGill University = Université McGill Montréal, Canada, University of Oxford Oxford, WHO Solidarity Response Fund and the German Federal Ministry of Health COVID-19 Research and Development. SeroTracker (led by RKA, including MW, HW, ZL, XM, CC, MYL, DB, JP, MPC, ML, MS, GRD, NI, CZ, SP, HPR, TY, KCN, DK, SAA, ND, CD, NAD, EL, RKI, ASB, ELB, AS, JC and NB) report funding from WHO, Canada COVID-19 Immunity Task Force through the Public Health Agency of Canada, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund., UNITY Study Collaborator Group: Rosemary A Audu, Jacob S Barnor, Enyew Birru, Henry K Bosa, Emily L Boucher, Annie Chauma-Mwale, Matthew P Cheng, Judy Chen, Cheryl Cohen, Tienhan S Dabakuyo-Yonli, Gabriel Deveaux, Boly Diop, Titus H Divala, Emily K Dokubo, Irene O Donkor, Claire Donnici, Nathan Duarte, Natalie A Duarte, Timothy G Evans, Lee Fairlie, Ousmane Faye, Anne von Gottberg,Tiffany G Harris, Natasha Ilincic, Elsie A Ilori, Jackie Kleynhans, Dayoung Kim, Olatunji M Kolawole, Jambo C Kondwani, Michael Liu, Emma Loeschnik, Sheila Makiala-Mandanda, Alexandre Manirakiza, Pinyi N Mawien, Portia C Mutevedzi, Jason M Mwenda, Eric M Osoro, Samiratou Ouedraogo, Sara Perlman-Arrow, Jesse Papenburg, Hude Quan, Hannah P Rahim, Karampreet Sachathep, Shobna Sawry, Mitchell Segal, Anabel Selemon, Judith Shang, Kristen A Stafford, Laura Steinhardt, Cheikh Talla, Halidou Tinto, Isidore T Traore, Joe A Theu, Ines Vigan-Womas, Tyler Williamson, Tingting Yan, Cedric P. Yansouni, Caseng Zhang. |
| بيانات النشر: | HAL CCSD BMJ Publishing Group Ltd |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, envir, socio |
| الوصف: | Introduction Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on Public Health and Social Measures (PHSM) and vaccine strategy.Methods We searched for seroprevalence studies conducted in Africa published 01-01-2020 to 30-12-2021 in Medline, Embase, Web of Science, and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity protocol for seroepidemiological investigations. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO. PROSPERO: CRD42020183634.Results We identified 54 full texts or early results, reporting 151 distinct seroprevalence studies in Africa Of these, 95 (63%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0% [95% CI: 1.0-9.2%] in Q2 2020 to 65.1% [95% CI: 56.3-73.0%] in Q3 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 97:1, ranging from 10:1 to 958:1) and steady over time. Seroprevalence was highly heterogeneous both within countries - urban vs. rural (lower seroprevalence for rural geographic areas), children vs. adults (children aged 0-9 years had the lowest seroprevalence) - and between countries and African sub-regions (Middle, Western and Eastern Africa associated with higher seroprevalence).Conclusion We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and protection against COVID-19 disease . |
| نوع الوثيقة: | article in journal/newspaper report |
| اللغة: | English |
| العلاقة: | https://hal.archives-ouvertes.fr/hal-03752589/file/2022.02.14.22270934v1.full.pdfTest; https://hal.archives-ouvertes.fr/hal-03752589Test |
| الإتاحة: | https://hal.archives-ouvertes.fr/hal-03752589/file/2022.02.14.22270934v1.full.pdfTest https://hal.archives-ouvertes.fr/hal-03752589Test |
| حقوق: | undefined |
| رقم الانضمام: | edsbas.E806607A |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |